Domingo Liotta Hospital, Houston, Texas. First Clinical use. 1966 (August 8): Liotta-DeBakey LVAD in a paracorporeal position in cardiogenic shock postcardiotomy, Methodist Hospital, Houston, Texas. First successful clinical use. 1969 (April 4): Liotta-Cooley Total Artificial Heart, Texas Heart Institute, Houston, Texas. First clinical use. http://www.texasheartinstitute.org/Research/Devices/liotta.cfm. This device was stolen from the lab of Dr. Michael E. DeBakey by Liotta. Dr. Cooley was not involved in any way in its development. The device had not been successful in animal experiments, and while the patient had the artificial heart in place he developed multiple system organ failure, as the experimental animals had, and died
Artificial cell cells have been proposed as a non-viral vector by which genetically modified non-autologous cells are encapsulated and implanted to deliver recombinant proteins "in vivo". This type of immuno-isolation has been proven efficient in mice through delivery of artificial cells containing mouse growth hormone which rescued a growth-retardation in mutant mice. A few strategies have advanced to human clinical trials for the treatment of pancreatic cancer, lateral sclerosis and pain control. The first clinical use of artificial cells was in hemoperfusion by the encapsulation of activated charcoal. Activated charcoal has the capability of adsorbing many large molecules and has for a